A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CNTO3157 Following an Escalating Single SC Dose to Healthy Japanese and Caucasian Subjects or a Single Intravenous Dose to Healthy Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2014
Price : $35 *
At a glance
- Drugs JNJ 42915925 (Primary) ; JNJ 42915925 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
- 22 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.